Stories
Natco Pharma Launches Carboplatin Injection in US Market, Shares Rise 2%
C
CNBC TV18•19-10-2026, 15:15
Natco Pharma Launches Carboplatin Injection in US Market, Shares Rise 2%
- •NATCO Pharma shares rose over 2 percent following the launch of Carboplatin Injection in the US market.
- •The drug is a generic version of Paraplatin and is used in the treatment of ovarian carcinoma.
- •The launch was executed through its US subsidiary NATCO Pharma USA LLC in collaboration with Teyro Labs Pvt Ltd.
- •Carboplatin Injection generated projected revenues of $27.8 million in the US for the twelve months ending in June 2026.
- •The company recently reported a decline in Q1FY27 profit and revenue figures compared to the previous fiscal year.
Key Questions Answered
Natco Pharma launched Carboplatin Injection, a generic version of Paraplatin, in the US market through its subsidiary NATCO Pharma USA LLC in collaboration with Teyro Labs Pvt Ltd. Following this announcement, the company's shares rose over 2% on Monday, October 19, 2026.
Carboplatin Injection is prescribed for managing advanced ovarian carcinoma, encompassing both first-line combination chemotherapy and supportive care for recurring malignancy following previous chemotherapeutic interventions.
In Q1FY27, Natco Pharma's profit dropped 57% year-over-year to ₹206.5 crore, while revenue slumped by 44.7% down to ₹735.2 crore. Additionally, EBITDA declined by 67.3% to ₹186.5 crore, and margins shrank sharply from 43% to 25.4%.
